5.9k Share this

Three billionaires with stakes in Moderna – co-founders Noubar Afeyan and Robert Langer, and investor Timothy Springer – made it onto Forbes’ list of the 400 richest Americans this year after their company put out one of three FDA-approved COVID vaccines.

Each of the men is worth over $3.5billion, and they were added to Forbes’ list on Tuesday based on SEC documents, stock prices from September and other financial records.

Since Moderna’s COVID-19 vaccine was approved by the US Food and Drug Administration, 152 million doses have been administered. The company was the first to test the vaccine on human subjects, further boosting its stock value.  

Although the pandemic destroyed hundreds of millions of jobs worldwide, the 400 richest people in the country saw their fortunes grow by a collective 40 percent, according to Forbes.

The publication’s latest list featured the most new names since 2007, most of them in the finance, tech and health care industries.

Moderna, based in Cambridge, Massachusetts has been rebuked for selling early doses of their RNA-based vaccine to the countries that bid the highest and for the extreme wealth that has been generated by its investors. 

However, Moderna CEO Stephane Bancel has said he expects vaccines to become available to ‘everyone on Earth’ next year. 

Along with competing vaccine manufacturers Pfizer and their German partner BioNTech, the company raked in billions of dollars in vaccine sales. Johnson & Johnson and Europe’s Astrozeneca said they don’t intend to profit from their vaccines.

Noubar Afeyan, 59, Moderna's current chairman, ranked 212th with a net worth about $3.7 billion

Noubar Afeyan, 59, Moderna's current chairman, ranked 212th with a net worth about $3.7 billion

Noubar Afeyan, 59, Moderna’s current chairman, ranked 212th with a net worth about $3.7 billion

Timothy Springer invested $5 million in Moderna at its onset, and now owns 3.5 percent of the company's shares. Presently, the Harvard Medical School professor is worth $4.4 billion, and is ranked 176 on the list.

Timothy Springer invested $5 million in Moderna at its onset, and now owns 3.5 percent of the company's shares. Presently, the Harvard Medical School professor is worth $4.4 billion, and is ranked 176 on the list.

Timothy Springer invested $5 million in Moderna at its onset, and now owns 3.5 percent of the company’s shares. Presently, the Harvard Medical School professor is worth $4.4 billion, and is ranked 176 on the list.

Robert Langer, number 222 on the list, owns 3 percent of Moderna's shares and has never sold one. The Massachusetts Institute of Technology professor is worth $3.5 billion

Robert Langer, number 222 on the list, owns 3 percent of Moderna's shares and has never sold one. The Massachusetts Institute of Technology professor is worth $3.5 billion

Robert Langer, number 222 on the list, owns 3 percent of Moderna’s shares and has never sold one. The Massachusetts Institute of Technology professor is worth $3.5 billion

Afeyan, 59, Moderna’s current chairman, ranked 212th with a net worth about $3.7 billion as of October 6, according to Forbes. The engineer, who was born in Beirut to Armenian parents, moved to Montreal during Lebanon’s civil war in 1975.

He has helped start more than 70 life sciences and technology businesses, and owns shares in 12 publicly-traded biotech companies, according to Forbes.

Throughout his career, according to Forbes, Noubar Afeyan has helped start more than 70 life sciences and technology businesses, and owns shares in 12 publicly-traded biotech companies

Throughout his career, according to Forbes, Noubar Afeyan has helped start more than 70 life sciences and technology businesses, and owns shares in 12 publicly-traded biotech companies

Throughout his career, according to Forbes, Noubar Afeyan has helped start more than 70 life sciences and technology businesses, and owns shares in 12 publicly-traded biotech companies

Springer invested $5million in Moderna at its onset, and now owns 3.5 percent of the company’s shares. Presently, the Harvard Medical School professor is worth $4.4 billion, and is ranked 176 on the list. He owns shares in three smaller biotech firms: Selecta Biosciences, Scholar Rock and Morphic Therapeutic.

Langer, number 222 on the list, owns 3 percent of Moderna’s shares and has never sold one. The Massachusetts Institute of Technology professor is worth $3.5 billion. He owns shares in SQZ Biotechnologies, Seer and Sigilon Therapeutics, which were founded by him and post-doctorate students from his lab.

He is thought to be the most cited engineer in history, with more than 350,000 citations. He has published more than 1,500 articles, and holds more than 1,400 patents and patent applications, more than 400 of which have been licensed by pharmacology and biotech companies.

Source: Daily Mail

5.9k Share this
You May Also Like

Borders ‘Are Not Open’ — 200K Migrants Show Otherwise

U.S. Customs and Border Protection officials declared the borders of the United…

Sheffield United striker Billy Sharp is attacked by a pitch invader at Nottingham Forest

Horrific moment Nottingham Forest fan floors Sheffield United striker Billy Sharp leaving…

Finally a police chief who’ll fight crime not culture wars, writes JENNI MURRAY

Logging on to my busy and informative neighbourhood app on a daily…

At least five people are injured as explosion rips through block of flats in Skelmersdale 

At least five people are injured as explosion rips through block of…

Conservative MP arrested on suspicion of rape is released on bail

Politicians were told not to publicly name a Tory MP arrested over…

Emma Raducanu admits people may think she’s ‘crazy’ after parting ways with three coaches

Emma Raducanu has opened up about her unusual pattern of replacing coaches,…

Family take legal action after son, 26, died from blood clots two weeks after AstraZeneca jab

The heartbroken family of a 26-year-old graduate who died from ‘catastrophic’ blood…

Plurality of Texas Voters Blame Biden and Congress for High Prices

The left’s narrative on high prices — blaming big oil and Russia’s…